Nanox Imaging to report Q1 2026 financial results on June 25
Nanox Imaging Ltd will announce Q1 2026 financial results on June 25, 2026, followed by a conference call with CEO Erez Meltzer and CFO Ran Daniel. The company's integrated medical imaging platform and ecosystem, including Nanox.ARC and Nanox.AI, underscore its focus on preventive healthcare.

*this image is generated using AI for illustrative purposes only.
Nanox Imaging Ltd, an innovative medical imaging technology company, will report its financial results for the quarter ended March 31, 2026, before market open on Thursday, June 25, 2026. The announcement will provide insights into the company's performance for Q1 2026, with a focus on its integrated medical imaging and healthcare services platform.
Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review the results and offer a business update. The call is scheduled to begin at 8:30 a.m. ET, offering stakeholders an opportunity to hear directly from leadership about the company's progress and strategic direction.
Interested parties can register for the conference call via the provided link. Additionally, a live webcast will be accessible through the same link, allowing broader access to the discussion. The webcast will also be available in the Investor Relations section of the Nanox website under Events and Presentations.
Nanox focuses on driving the transition to preventive healthcare through its end-to-end medical imaging platform. The company combines affordable imaging hardware, AI-based solutions, cloud-based software, and remote radiology access to enhance early detection and clinical efficiency. Its ecosystem includes Nanox.ARC, Nanox.AI, Nanox.CLOUD, Nanox.MARKETPLACE, and Nanox Health IT, all designed to expand the reach of medical imaging beyond traditional settings.
The company's vision is to lower barriers to adoption and improve utilization of medical imaging globally. By leveraging proprietary digital X-ray technology and AI-driven analytics, Nanox aims to support early disease detection and improve patient outcomes. The upcoming financial results will shed light on the company's progress toward these goals.
What key performance indicators will Nanox prioritize to demonstrate the success of its integrated medical imaging platform?
How might the Q1 2026 results influence investor confidence in Nanox's ability to scale its preventive healthcare model globally?
What strategic partnerships or expansions could Nanox pursue following the Q1 earnings announcement to accelerate market adoption?
























